SG11201806548UA - Radio-pharmaceutical complexes - Google Patents
Radio-pharmaceutical complexesInfo
- Publication number
- SG11201806548UA SG11201806548UA SG11201806548UA SG11201806548UA SG11201806548UA SG 11201806548U A SG11201806548U A SG 11201806548UA SG 11201806548U A SG11201806548U A SG 11201806548UA SG 11201806548U A SG11201806548U A SG 11201806548UA SG 11201806548U A SG11201806548U A SG 11201806548UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tissue
- targeting
- pct
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/162555 Al 28 September 2017 (28.09.2017) WIPO I PCT 111111111111110111011111111111010111110111011111111011111111111111111111111111110111111 (51) International Patent Classification: A61K 51/10 (2006.01) A61K 103/40 (2006.01) C07K 16/32 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/056503 (22) International Filing Date: 20 March 2017 (20.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16162123.0 24 March 2016 (24.03.2016) EP (71) Applicants: BAYER PHARMA AKTIENGESELL- SCHAFT [DE/DE]; Miillerstr. 178, 13353 Berlin (DE). BAYER AS [NO/NO]; Drammensveien 288, N-0283 Oslo (NO). (72) Inventors: LINDEN, Lars; Am Altenlande 2, 58285 Gevelsberg (DE). CUTHBERTSON, Alan; Orrevein 14, N-9789 Oslo (NO). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) W O 20 17 / 16 2555 Al (54) Title: RADIO-PHARMACEUTICAL COMPLEXES (57) : The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-tar - geting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16162123 | 2016-03-24 | ||
PCT/EP2017/056503 WO2017162555A1 (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806548UA true SG11201806548UA (en) | 2018-08-30 |
Family
ID=55745553
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806548UA SG11201806548UA (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
SG10202009424TA SG10202009424TA (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202009424TA SG10202009424TA (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Country Status (19)
Country | Link |
---|---|
US (2) | US11260136B2 (en) |
EP (1) | EP3432936A1 (en) |
JP (2) | JP2019513699A (en) |
CN (1) | CN108778347A (en) |
AR (1) | AR107957A1 (en) |
AU (1) | AU2017239018A1 (en) |
BR (1) | BR112018069485A2 (en) |
CA (1) | CA3018607A1 (en) |
CL (1) | CL2018002695A1 (en) |
CO (1) | CO2018010024A2 (en) |
IL (1) | IL261329B (en) |
JO (1) | JOP20170072B1 (en) |
MX (1) | MX2018011629A (en) |
PE (1) | PE20190168A1 (en) |
SG (2) | SG11201806548UA (en) |
TW (1) | TWI757273B (en) |
UA (1) | UA125749C2 (en) |
UY (1) | UY37167A (en) |
WO (1) | WO2017162555A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210187134A1 (en) | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
WO2020169537A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
NO312708B1 (en) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioactive liposomes for therapy |
NO313180B1 (en) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Visiting alpha particles emitting radiopharmaceuticals |
GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
SI1850874T1 (en) * | 2005-02-23 | 2014-01-31 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
US20090214420A1 (en) * | 2005-04-01 | 2009-08-27 | Medvet Science Pty. Ltd. | Method of Diagnosis and Treatment and Agents Useful for Same |
WO2008019290A2 (en) * | 2006-08-04 | 2008-02-14 | Astrazeneca Ab | Human antibodies to erbb 2 |
EP2423201B1 (en) | 2006-08-15 | 2017-10-04 | The Regents of the University of California | Luminescent macrocyclic lanthanide complexes |
EP2488199A1 (en) * | 2009-10-14 | 2012-08-22 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
MA41176A (en) * | 2014-12-17 | 2017-10-24 | Bayer As | RADIO-PHARMACEUTICAL COMPLEXES |
-
2017
- 2017-03-20 CN CN201780017966.8A patent/CN108778347A/en active Pending
- 2017-03-20 WO PCT/EP2017/056503 patent/WO2017162555A1/en active Application Filing
- 2017-03-20 BR BR112018069485A patent/BR112018069485A2/en unknown
- 2017-03-20 MX MX2018011629A patent/MX2018011629A/en unknown
- 2017-03-20 PE PE2018001861A patent/PE20190168A1/en unknown
- 2017-03-20 JP JP2018547324A patent/JP2019513699A/en active Pending
- 2017-03-20 US US16/087,040 patent/US11260136B2/en active Active
- 2017-03-20 EP EP17710976.6A patent/EP3432936A1/en active Pending
- 2017-03-20 AU AU2017239018A patent/AU2017239018A1/en active Pending
- 2017-03-20 SG SG11201806548UA patent/SG11201806548UA/en unknown
- 2017-03-20 CA CA3018607A patent/CA3018607A1/en active Pending
- 2017-03-20 SG SG10202009424TA patent/SG10202009424TA/en unknown
- 2017-03-20 UA UAA201810278A patent/UA125749C2/en unknown
- 2017-03-21 TW TW106109303A patent/TWI757273B/en active
- 2017-03-22 JO JOP/2017/0072A patent/JOP20170072B1/en active
- 2017-03-23 AR ARP170100720A patent/AR107957A1/en unknown
- 2017-03-23 UY UY0001037167A patent/UY37167A/en not_active Application Discontinuation
-
2018
- 2018-08-22 IL IL261329A patent/IL261329B/en active IP Right Grant
- 2018-09-24 CL CL2018002695A patent/CL2018002695A1/en unknown
- 2018-09-24 CO CONC2018/0010024A patent/CO2018010024A2/en unknown
-
2022
- 2022-01-21 US US17/581,808 patent/US20220143229A1/en active Pending
- 2022-08-30 JP JP2022136797A patent/JP2022173214A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3432936A1 (en) | 2019-01-30 |
US20190091354A1 (en) | 2019-03-28 |
IL261329A (en) | 2018-10-31 |
CO2018010024A2 (en) | 2018-10-22 |
CL2018002695A1 (en) | 2019-01-18 |
TWI757273B (en) | 2022-03-11 |
TW201736389A (en) | 2017-10-16 |
SG10202009424TA (en) | 2020-11-27 |
BR112018069485A2 (en) | 2019-07-30 |
MX2018011629A (en) | 2019-03-14 |
JP2019513699A (en) | 2019-05-30 |
PE20190168A1 (en) | 2019-02-01 |
AU2017239018A1 (en) | 2018-08-16 |
UA125749C2 (en) | 2022-06-01 |
UY37167A (en) | 2017-10-31 |
US11260136B2 (en) | 2022-03-01 |
JOP20170072B1 (en) | 2022-03-14 |
CA3018607A1 (en) | 2017-09-28 |
AR107957A1 (en) | 2018-07-04 |
CN108778347A (en) | 2018-11-09 |
WO2017162555A1 (en) | 2017-09-28 |
IL261329B (en) | 2021-04-29 |
US20220143229A1 (en) | 2022-05-12 |
JP2022173214A (en) | 2022-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810967VA (en) | Radio-pharmaceutical complexes | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201807472TA (en) | Amanitin conjugates | |
SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201808003RA (en) | Bromodomain inhibitors | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201908977SA (en) | Niraparib formulations | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201808686VA (en) | Synthesis of indazoles |